Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.41 |
| ▸ | METAP2 | P50579 | 6/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CDK9 | P50750 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641259 | 1.00 | TDO2 (0.43) | TDO2IDO1CDK2FLT3CCNA1 | |
| SCHEMBL19948646 | 0.83 | IDO1 (0.47) | TDO2IDO1METAP2NOS1AXL | |
| SCHEMBL27358505 | 0.83 | IDO1 (0.46) | TDO2IDO1CDK2FLT3CCNA1 | |
| SCHEMBL30410207 | 0.83 | IDO1 (0.47) | TDO2IDO1METAP2NOS1AXL | |
| SCHEMBL13676393 | 0.81 | IDO1 (0.44) | TDO2IDO1CDK2FLT3CCNA1 | |
| SCHEMBL24876403 | 0.79 | IDO1 (0.42) | TDO2IDO1CDK2FLT3CCNA1 | |
| SCHEMBL21196002 | 0.79 | IDO1 (0.43) | TDO2IDO1CDK2FLT3CCNA1 | |
| SCHEMBL29937471 | 0.79 | IDO1 (0.47) | TDO2IDO1METAP2NOS1AXL | |
| SCHEMBL21196262 | 0.79 | IDO1 (0.47) | TDO2IDO1METAP2NOS1AXL | |
| SCHEMBL31041019 | 0.79 | IDO1 (0.43) | TDO2IDO1CDK2FLT3CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-110267957-B | Quinazoline compounds | 安斯泰来制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| EP-3578560-B1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3578560-B1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-10774082-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10774082-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20200140437-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200140437-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10556906-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-10556906-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2019-09-26 | — | — | US | disclosed |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140437-A1 | QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | TDO2 4557/4885IDO1 3409/4885CDK2 474/4885 |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | TDO2 1808/4885IDO1 1410/4885CDK2 18/4885 |
| US-10556906-B2 | Quinazoline compound | KRAS, NRAS, HRAS | TDO2 4557/4885IDO1 3409/4885CDK2 474/4885 |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | TDO2 4557/4885IDO1 3409/4885CDK2 474/4885 |
| US-10774082-B2 | Quinazoline compound | KRAS, NRAS, HRAS | TDO2 4557/4885IDO1 3409/4885CDK2 474/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | TDO2 4735/4885IDO1 4847/4885CDK2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.